(-)-Epigallocatechin Gallate
Based on 65 publication(s) in Google Scholar
(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma.
For research use only. We do not sell to patients.
- Purity: 99.58%
- CAS No.: 989-51-5
- Formula: C22H18O11
- Molecular Weight:458.37
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) (-)-Epigallocatechin Gallate
More- Cancer Res. 2022 Sep 16;82(18):3223-3235. [Abstract]
- J Nanobiotechnology. 2025 Mar 29;23(1):258. [Abstract]
- Adv Sci (Weinh). 2026 Jul 28:e76721.
- Biomaterials. 2021 Aug:275:120952. [Abstract]
- J Control Release. 2026 May 10:393:114824. [Abstract]
- Cell Death Dis. 2026 Apr 24;17(1):548. [Abstract]
- Cell Death Dis. 2023 Jul 29;14(7):481. [Abstract]
- Phytomedicine. 2025 May:140:156572. [Abstract]
- Phytomedicine. 2025 May:140:156484. [Abstract]
- Food Res Int. 2025 Oct:218:116882. [Abstract]
- EMBO Mol Med. 2024 Aug;16(8):1817-1839. [Abstract]
- ACS Appl Mater Interfaces. 2025 Oct 15;17(41):56846-56860. [Abstract]
- Br J Cancer. 2021 Jan;124(2):425-436. [Abstract]
- Aging Cell. 2020 Oct;19(10):e13217. [Abstract]
- Anal Chem. 2025 Dec 19. [Abstract]
- J Med Chem. 2023 Mar 23;66(6):4106-4130. [Abstract]
- Anal Chem. 2020 Mar 17;92(6):4419-4426. [Abstract]
- J Agric Food Chem. 2026 Apr 15;74(14):11579-11591. [Abstract]
- Biochem Pharmacol. 2026 Oct:252:118252.
- Biochem Pharmacol. 2025 Dec;242(Pt 4):117443. [Abstract]
- Cell Mol Life Sci. 2022 Nov 30;79(12):611. [Abstract]
- Food Funct. 2022 Sep 22;13(18):9544-9558. [Abstract]
- Cells. 2026 Feb 3;15(3):287. [Abstract]
- Int Immunopharmacol. 2026 Sep 1:184:116932. [Abstract]
- ACS Omega. 2025 Dec 8;10(50):62145-62156. [Abstract]
- Food Sci Nutr. 2025 Aug 11;13(8):e70736. [Abstract]
- Food Sci Nutr. 2025 Feb 25;13(3):e4687. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- Sci Rep. 2024 Dec 28;14(1):31474. [Abstract]
- Nanomaterials. 2019 Mar 8;9(3):396. [Abstract]
- Environ Toxicol Pharmacol. 2026 Mar:122:104954. [Abstract]
- Neurochem Res. 2022 Nov;47(11):3464-3475. [Abstract]
- J Neurosci. 2025 Aug 27;45(35):e0523252025. [Abstract]
- FASEB J. 2025 May 15;39(9):e70562. [Abstract]
- Biochim Biophys Acta Mol Cell Res. 2025 Mar;1872(3):119902. [Abstract]
- Antiviral Res. 2022 Jun;202:105325. [Abstract]
- Fish Shellfish Immunol. 2023 Mar:134:108582. [Abstract]
- Microbiol Spectr. 2022 Apr 27;10(2):e0227621. [Abstract]
- Microb Pathog. 2024 Nov:196:106960. [Abstract]
- Pathogens. 2026 Mar 20;15(3):334. [Abstract]
- Viruses. 2023 Dec 16;15(12):2447. [Abstract]
- Viruses. 2020 Feb 4;12(2):176. [Abstract]
- Bioorg Med Chem. 2026 Jul:138:118664. [Abstract]
- J Cancer. 2019 Oct 21;10(26):6543-6556. [Abstract]
- Open Biol. 2024 Jun;14(6):230427. [Abstract]
- Oral Dis. 2019 May;25(4):1175-1184. [Abstract]
- PeerJ. 2024 May 28:12:e17488. [Abstract]
- Vet Microbiol. 2026 May:316:110992. [Abstract]
- Toxicol In Vitro. 2023 Sep:91:105626. [Abstract]
- Int J Cosmet Sci. 2016 Oct;38(5):512-23. [Abstract]
- Biochem Biophys Res Commun. 2020 Feb 19;522(4):862-868. [Abstract]
- Biochem Biophys Res Commun. 2018 Sep 3;503(1):297-303. [Abstract]
- Oncol Lett. 2017 Nov;14(5):6314-6320. [Abstract]
- bioRxiv. 2026 Jun 23.
- Nan Fang Yi Ke Da Xue Xue Bao. 2026 Jun 20;46(6):1323-1330. [Abstract]
- bioRxiv. 2026 Mar 12.
- bioRxiv. 2026 Jan 26.
- Res Sq. 2025 Nov 4.
- Res Sq. 2025 Jan 31.
- Res Sq. 2025 Feb 05.
- Biomed Pharmacother. 2024 May:174:116542. [Abstract]
- Sci Total Environ. 2024 Mar 1:914:169923. [Abstract]
- Research Square Print. August 25th, 2022.
- Oxid Med Cell Longev. 2022 Jun 6:2022:7291774. [Abstract]
- Oxid Med Cell Longev. 2022 Jan 17;2022:8038857. [Abstract]
-
Others
-
Bio/Physico-chemical Assay
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
WB
All Endogenous Metabolite Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
EGFR |
HER2 |
HER3 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 3T3-L1 | IC50 |
112 μM
Compound: EGCG
|
Antiadipogenic activity in mouse 3T3L1 cells assessed as differentiation of preadipocytes to adipocytes after 8 days by spectrophotometry
Antiadipogenic activity in mouse 3T3L1 cells assessed as differentiation of preadipocytes to adipocytes after 8 days by spectrophotometry
|
[PMID: 23628332] |
| 3T3-L1 | IC50 |
25 μM
Compound: EGCG, (-)-epigalocatechin gallate
|
Inhibition of G6PD-mediated NADPH production in mouse 3T3-L1 cells
Inhibition of G6PD-mediated NADPH production in mouse 3T3-L1 cells
|
[PMID: 18313308] |
| A-431 | EC50 |
266 μM
Compound: 1, EGCG
|
Antiproliferative activity against human A431 cells overexpressing ErbB in complete medium assessed as cell viability after 48 hrs by WST-1 assay
Antiproliferative activity against human A431 cells overexpressing ErbB in complete medium assessed as cell viability after 48 hrs by WST-1 assay
|
[PMID: 24456004] |
| A-431 | EC50 |
38 μM
Compound: 1, EGCG
|
Antiproliferative activity against human A431 cells overexpressing ErbB in serum-free medium assessed as cell viability after 48 hrs by WST-1 assay
Antiproliferative activity against human A431 cells overexpressing ErbB in serum-free medium assessed as cell viability after 48 hrs by WST-1 assay
|
[PMID: 24456004] |
| A549 | IC50 |
185 μM
Compound: EGCG
|
Antiproliferative activity against human A549 cells expressing FASN assessed as reduction in cell viability after 72 hrs by MTS assay
Antiproliferative activity against human A549 cells expressing FASN assessed as reduction in cell viability after 72 hrs by MTS assay
|
[PMID: 31422225] |
| A549 | IC50 |
29 μM
Compound: EGCG
|
Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 28654265] |
| BXPC-3 | IC50 |
33 μM
Compound: EGCG
|
Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 28654265] |
| CHO | IC50 |
271 μM
Compound: EGCG
|
Cytotoxicity against wild type CHO cells after 48 hrs by fluorescence based CellTiter-Glo assay
Cytotoxicity against wild type CHO cells after 48 hrs by fluorescence based CellTiter-Glo assay
|
[PMID: 23327877] |
| CHO | IC50 |
3.2 μM
Compound: EGCG
|
Cytotoxicity against CHO cells expressing OATP1B3 haplotype 1 after 48 hrs by fluorescence based CellTiter-Glo assay
Cytotoxicity against CHO cells expressing OATP1B3 haplotype 1 after 48 hrs by fluorescence based CellTiter-Glo assay
|
[PMID: 23327877] |
| CHO | IC50 |
7.7 μM
Compound: EGCG
|
Cytotoxicity against CHO cells expressing OATP1B1*1b after 48 hrs by fluorescence based CellTiter-Glo assay
Cytotoxicity against CHO cells expressing OATP1B1*1b after 48 hrs by fluorescence based CellTiter-Glo assay
|
[PMID: 23327877] |
| COLO 201 | IC50 |
38 μM
Compound: EGCG
|
Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 28654265] |
| CV-1 | IC50 |
12.05 μM
Compound: (-)-EGCG
|
Antiviral activity against Human herpesvirus 2 isolate P27 infected in African green monkey CV1 cells
Antiviral activity against Human herpesvirus 2 isolate P27 infected in African green monkey CV1 cells
|
[PMID: 18195068] |
| CV-1 | IC50 |
12.27 μM
Compound: (-)-EGCG
|
Antiviral activity against Human herpesvirus 2 isolate P2 infected in African green monkey CV1 cells
Antiviral activity against Human herpesvirus 2 isolate P2 infected in African green monkey CV1 cells
|
[PMID: 18195068] |
| CV-1 | IC50 |
12.47 μM
Compound: (-)-EGCG
|
Antiviral activity against Human herpesvirus 2 isolate P22 infected in African green monkey CV1 cells
Antiviral activity against Human herpesvirus 2 isolate P22 infected in African green monkey CV1 cells
|
[PMID: 18195068] |
| CV-1 | IC50 |
12.48 μM
Compound: (-)-EGCG
|
Antiviral activity against Human herpesvirus 2 isolate P11 infected in African green monkey CV1 cells
Antiviral activity against Human herpesvirus 2 isolate P11 infected in African green monkey CV1 cells
|
[PMID: 18195068] |
| CV-1 | IC50 |
12.5 μM
Compound: (-)-EGCG
|
Antiviral activity against Human herpesvirus 2 isolate P12 infected in African green monkey CV1 cells
Antiviral activity against Human herpesvirus 2 isolate P12 infected in African green monkey CV1 cells
|
[PMID: 18195068] |
| CV-1 | IC50 |
12.5 μM
Compound: (-)-EGCG
|
Antiviral activity against Human herpesvirus 2 isolate P47 infected in African green monkey CV1 cells
Antiviral activity against Human herpesvirus 2 isolate P47 infected in African green monkey CV1 cells
|
[PMID: 18195068] |
| CV-1 | IC50 |
25 μM
Compound: (-)-EGCG
|
Antiviral activity against Human herpesvirus 2 strain 333 strain 333 infected in African green monkey CV-1 cells
Antiviral activity against Human herpesvirus 2 strain 333 strain 333 infected in African green monkey CV-1 cells
|
[PMID: 18195068] |
| H9 | EC50 |
7 μg/mL
Compound: 8
|
Inhibition of HIV-1 replication in H9 (human lymphoma) cells.
Inhibition of HIV-1 replication in H9 (human lymphoma) cells.
|
10.1016/0960-894X(96)00095-9 |
| H9 | IC50 |
8 μg/mL
Compound: 8
|
Inhibition of uninfected H9 lymphocytic cell growth
Inhibition of uninfected H9 lymphocytic cell growth
|
10.1016/0960-894X(96)00095-9 |
| HCT-116 | IC50 |
161 μM
Compound: EGCG
|
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 12880319] |
| HCT-116 | IC50 |
5 μM
Compound: 54
|
Antiproliferative activity against human HCT-116 cells assessed as decrease in cell growth incubated for 24 hrs by MTS assay
Antiproliferative activity against human HCT-116 cells assessed as decrease in cell growth incubated for 24 hrs by MTS assay
|
[PMID: 33445154] |
| HeLa | IC50 |
1.08 μM
Compound: 4, EGCG
|
Inhibition of telomerase in human HeLa cells using 5'-AAT CCG TCG AGC AGA GTT-3' as substrate incubated for 15 mins prior to extension reaction followed by compound washout by spin-telomeric repeat amplification protocol
Inhibition of telomerase in human HeLa cells using 5'-AAT CCG TCG AGC AGA GTT-3' as substrate incubated for 15 mins prior to extension reaction followed by compound washout by spin-telomeric repeat amplification protocol
|
[PMID: 22413845] |
| HeLa | IC50 |
1.18 μM
Compound: 4, EGCG
|
Inhibition of telomerase in human HeLa cells using 5'-AAT CCG TCG AGC AGA GTT-3' as substrate incubated for 15 mins prior to extension reaction by telomeric repeat amplification protocol
Inhibition of telomerase in human HeLa cells using 5'-AAT CCG TCG AGC AGA GTT-3' as substrate incubated for 15 mins prior to extension reaction by telomeric repeat amplification protocol
|
[PMID: 22413845] |
| HL-60 | IC50 |
9.4 μM
Compound: EGCG
|
Antiproliferative activity against human HL60 cells after 3 days
Antiproliferative activity against human HL60 cells after 3 days
|
[PMID: 18693020] |
| HSC-T6 | IC50 |
29.8 μM
Compound: EGCG
|
Antiproliferative activity against rat HSC-T6 cells assessed as reduction in cell viability
Antiproliferative activity against rat HSC-T6 cells assessed as reduction in cell viability
|
[PMID: 25322455] |
| HSC-T6 | IC50 |
31.6 μM
Compound: (-)-EGCG
|
Inhibition of cell proliferation of activated rat HSC-T6 cells incubated for 24 hrs by MTT assay
Inhibition of cell proliferation of activated rat HSC-T6 cells incubated for 24 hrs by MTT assay
|
[PMID: 28257196] |
| HSC-T6 | IC50 |
9.9 μM
Compound: EGCG
|
Antiproliferative activity against rat HSC-T6 cells after 48 hrs by MTT assay
Antiproliferative activity against rat HSC-T6 cells after 48 hrs by MTT assay
|
[PMID: 18052323] |
| HSC-T6 | IC50 |
9.9 μM
Compound: EGCG
|
Antifibrotic activity against rat HSC-T6 cells assessed as inhibition of proliferation after 48 hrs by BrdU incorporation assay
Antifibrotic activity against rat HSC-T6 cells assessed as inhibition of proliferation after 48 hrs by BrdU incorporation assay
|
[PMID: 21504848] |
| HT-22 | IC50 |
23.8 μM
Compound: 42; EGCG
|
Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
|
[PMID: 36876904] |
| HT-29 | IC50 |
60 μM
Compound: EGCG
|
Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 28654265] |
| Huh-7 | IC50 |
20 μM
Compound: 5, EGCG
|
Antiviral activity against HCV genotype 1a assessed as inhibition of viral entry into Huh7 cells treated for 2 hr followed by 28 hrs incubation period in compound-free medium by immunofluorescence assay
Antiviral activity against HCV genotype 1a assessed as inhibition of viral entry into Huh7 cells treated for 2 hr followed by 28 hrs incubation period in compound-free medium by immunofluorescence assay
|
[PMID: 25103601] |
| Jurkat | IC50 |
1 μM
Compound: (-)-EGCG
|
Inhibition of chymotrypsin-like activity of human 26S proteasome extracted from human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Arg-AMC as substrate after 90 mins by fluorometric analysis
Inhibition of chymotrypsin-like activity of human 26S proteasome extracted from human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Arg-AMC as substrate after 90 mins by fluorometric analysis
|
[PMID: 30776692] |
| Jurkat | IC50 |
18 μM
Compound: (-)-EGCG
|
Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Arg-AMC as substrate preincubated for 12 hrs followed by addition of substrate and measured after 2 hrs by fluoro
Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Arg-AMC as substrate preincubated for 12 hrs followed by addition of substrate and measured after 2 hrs by fluoro
|
[PMID: 30776692] |
| L1210 | IC50 |
690 μM
Compound: EGCG
|
Cytotoxicity against mouse L1210 cells after 24 hrs by WST8 assay
Cytotoxicity against mouse L1210 cells after 24 hrs by WST8 assay
|
[PMID: 18951028] |
| L929 | IC50 |
82.3 μM
Compound: EGCG
|
Cytotoxicity against mouse L929 cells after 3 days by MTS assay
Cytotoxicity against mouse L929 cells after 3 days by MTS assay
|
[PMID: 25985195] |
| LN-229 | IC50 |
15 μM
Compound: EGCG
|
Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 28654265] |
| LX-2 | CC50 |
>100 μM
Compound: EGCG
|
Cytotoxicity against human LX2 cells assessed as cell death incubated for 24 hrs by MTT assay
Cytotoxicity against human LX2 cells assessed as cell death incubated for 24 hrs by MTT assay
|
[PMID: 34610571] |
| MCF7 | IC50 |
4 μM
Compound: EGCG
|
Antiproliferative activity against human MCF7 cells
Antiproliferative activity against human MCF7 cells
|
[PMID: 30048133] |
| MCF7 | IC50 |
74 μM
Compound: 38; ECGC
|
Antiproliferative activity against human MCF7 cells
Antiproliferative activity against human MCF7 cells
|
[PMID: 31663736] |
| MCF7 | IC50 |
74 μM
Compound: EGCG, 38
|
Antiproliferative activity against human MCF7 cells
Antiproliferative activity against human MCF7 cells
|
[PMID: 25141341] |
| MDA-MB-231 | IC50 |
149 μM
Compound: 1; EGCG
|
Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 37776575] |
| MDA-MB-231 | IC50 |
76.1 μM
Compound: EGCG
|
Antiproliferative activity against human MDA-MB-231 cells after 4 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 4 hrs by MTT assay
|
[PMID: 25453798] |
| MDA-MB-231 | IC50 |
83 μM
Compound: EGCG
|
Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 28654265] |
| MDCK | CC50 |
>100 μM
Compound: EGCG
|
Cytotoxicity against MDCK cells incubated for 48 hrs by MTT assay
Cytotoxicity against MDCK cells incubated for 48 hrs by MTT assay
|
[PMID: 36521178] |
| MDCK | CC50 |
>200 μM
Compound: EGCG
|
Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31954881] |
| MDCK | CC50 |
275 μM
Compound: 1, EGCG
|
Cytotoxicity against MDCK cells by MTT assay
Cytotoxicity against MDCK cells by MTT assay
|
[PMID: 18547804] |
| MDCK | CC50 |
275.4 μM
Compound: 56; EGCG
|
Cytotoxicity against MDCK cells after 48 hrs by MTT assay
Cytotoxicity against MDCK cells after 48 hrs by MTT assay
|
[PMID: 28118010] |
| MDCK | EC50 |
94.6 μM
Compound: 1, EGCG
|
Antiviral activity against Influenza A/PR8/34(H1N1)) in dog MDCK cells
Antiviral activity against Influenza A/PR8/34(H1N1)) in dog MDCK cells
|
[PMID: 18547804] |
| MDCK | ED50 |
8.3 μM
Compound: 3, EGCG
|
Antiviral activity against influenza A virus (A/swine/OH/511445/2007(H1N1)) Oh7 infected in MDCK cells assessed as inhibition of viral replication after 4 days by quantitative RT-PCR
Antiviral activity against influenza A virus (A/swine/OH/511445/2007(H1N1)) Oh7 infected in MDCK cells assessed as inhibition of viral replication after 4 days by quantitative RT-PCR
|
[PMID: 22115591] |
| MDCK | IC50 |
41.25 μM
Compound: 1, EGCG
|
Antiviral activity against Influenza A virus (A/Memphis/1/71(H3N2)) in MDCK cells after 16 hrs by focus forming assay
Antiviral activity against Influenza A virus (A/Memphis/1/71(H3N2)) in MDCK cells after 16 hrs by focus forming assay
|
[PMID: 17420124] |
| MEF | GI50 |
14 μM
Compound: 34, EGCG
|
Growth inhibition of Pin1-deficient MEF
Growth inhibition of Pin1-deficient MEF
|
[PMID: 23796453] |
| MEF | GI50 |
7 μM
Compound: 34, EGCG
|
Growth inhibition of MEF expressing Pin1
Growth inhibition of MEF expressing Pin1
|
[PMID: 23796453] |
| NCI-H1299 | IC50 |
>80 μM
Compound: EGCG
|
Antiproliferative activity in human NCI-H1299 cells after 72 hrs
Antiproliferative activity in human NCI-H1299 cells after 72 hrs
|
[PMID: 29530347] |
| NCI-H1299 | IC50 |
20.6 μM
Compound: EGCG
|
Antiproliferative activity against human NCI-H1299 cells expressing FASN assessed as reduction in cell viability after 72 hrs by MTS assay
Antiproliferative activity against human NCI-H1299 cells expressing FASN assessed as reduction in cell viability after 72 hrs by MTS assay
|
[PMID: 31422225] |
| NCI-H1650 | IC50 |
24.8 μM
Compound: EGCG
|
Antiproliferative activity against human NCI-H1650 cells expressing FASN assessed as reduction in cell viability after 72 hrs by MTS assay
Antiproliferative activity against human NCI-H1650 cells expressing FASN assessed as reduction in cell viability after 72 hrs by MTS assay
|
[PMID: 31422225] |
| NCI-H1703 | IC50 |
17.1 μM
Compound: EGCG
|
Antiproliferative activity against human NCI-H1703 cells expressing FASN assessed as reduction in cell viability after 72 hrs by MTS assay
Antiproliferative activity against human NCI-H1703 cells expressing FASN assessed as reduction in cell viability after 72 hrs by MTS assay
|
[PMID: 31422225] |
| NCI-H460 | IC50 |
18 μM
Compound: EGCG
|
Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 28654265] |
| PANC-1 | IC50 |
62 μM
Compound: EGCG
|
Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 28654265] |
| PC-12 | IC50 |
0.03 μM
Compound: 69; (-)-EGCG
|
Neuroprotective activity against rat PC12 cells assessed as decrease in H2O2-induced intracellular Ca2+ level preincubated for 12 hrs followed by H2O2-stimulation and measured after 12 hrs by Fluo-3 AM dye based flow cytometry
Neuroprotective activity against rat PC12 cells assessed as decrease in H2O2-induced intracellular Ca2+ level preincubated for 12 hrs followed by H2O2-stimulation and measured after 12 hrs by Fluo-3 AM dye based flow cytometry
|
[PMID: 38295689] |
| PC-9 | IC50 |
77.4 μM
Compound: EGCG
|
Antiproliferative activity against human PC9 cells harboring FASN expression and EGFR delE746-A750 mutant assessed as reduction in cell viability after 72 hrs by MTS assay
Antiproliferative activity against human PC9 cells harboring FASN expression and EGFR delE746-A750 mutant assessed as reduction in cell viability after 72 hrs by MTS assay
|
[PMID: 31422225] |
| Peritoneal macrophage cell | IC50 |
436.3 μM
Compound: 1, EGCG
|
Cytotoxicity against Swiss mouse peritoneal macrophages after 72 hrs by Alamar blue assay
Cytotoxicity against Swiss mouse peritoneal macrophages after 72 hrs by Alamar blue assay
|
[PMID: 24106750] |
| RAW264.7 | IC50 |
29.8 μM
Compound: EGCG
|
Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells assessed as decrease in TRAP-positive multi-nucleated cells after 5 days
Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells assessed as decrease in TRAP-positive multi-nucleated cells after 5 days
|
[PMID: 21456521] |
| Sf9 | IC50 |
0.5 μM
Compound: 9, EGCG
|
Inhibition of His6-tagged human recombinant DNMT1 expressed in insect Sf9 cells assessed as reduction in DNA methyltransferase activity using 5'-biotinylated 45-bp unmethylated or hemimethylated oligonucleotide substrates and [3H]-AdoMet by liquid scintil
Inhibition of His6-tagged human recombinant DNMT1 expressed in insect Sf9 cells assessed as reduction in DNA methyltransferase activity using 5'-biotinylated 45-bp unmethylated or hemimethylated oligonucleotide substrates and [3H]-AdoMet by liquid scintil
|
[PMID: 25406944] |
| SH-SY5Y | EC50 |
39.87 nM
Compound: EGCG
|
Neuroprotection against beta-amyloid peptide 1-42-induced toxicity in human SH-SY5Y cells assessed as lactate dehydrogenase release
Neuroprotection against beta-amyloid peptide 1-42-induced toxicity in human SH-SY5Y cells assessed as lactate dehydrogenase release
|
[PMID: 19138859] |
| SK-BR-3 | EC50 |
100 μM
Compound: 1, EGCG
|
Antiproliferative activity against human SKBR3 cells overexpressing ErbB in serum-free medium assessed as cell viability after 48 hrs by WST-1 assay
Antiproliferative activity against human SKBR3 cells overexpressing ErbB in serum-free medium assessed as cell viability after 48 hrs by WST-1 assay
|
[PMID: 24456004] |
| SK-BR-3 | EC50 |
195 μM
Compound: 1, EGCG
|
Antiproliferative activity against human SKBR3 cells overexpressing ErbB in complete medium assessed as cell viability after 48 hrs by WST-1 assay
Antiproliferative activity against human SKBR3 cells overexpressing ErbB in complete medium assessed as cell viability after 48 hrs by WST-1 assay
|
[PMID: 24456004] |
| SK-BR-3 | IC50 |
149 μM
Compound: 4, EGCG
|
Cytotoxicity against human SKBR3 cells after 48 hrs by MTT assay
Cytotoxicity against human SKBR3 cells after 48 hrs by MTT assay
|
[PMID: 22559865] |
| SK-BR-3 | IC50 |
150 μM
Compound: 27, EGCG
|
Cytotoxicity against human SKBR3 cells
Cytotoxicity against human SKBR3 cells
|
[PMID: 21726077] |
| SK-BR-3 | IC50 |
4 μM
Compound: EGCG
|
Antiproliferative activity against human SKBR3 cells
Antiproliferative activity against human SKBR3 cells
|
[PMID: 30048133] |
| SK-MEL-2 | IC50 |
31 μM
Compound: EGCG
|
Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 28654265] |
| SW480 | IC50 |
195 μM
Compound: EGCG
|
Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
|
[PMID: 12880319] |
| T47D | IC50 |
57 μM
Compound: EGCG
|
Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 28654265] |
| T98G | IC50 |
166 μM
Compound: EGCG
|
Antiproliferative activity against human T98G cells after 24 hrs by EZ-Tox assay
Antiproliferative activity against human T98G cells after 24 hrs by EZ-Tox assay
|
[PMID: 26631318] |
| U-266 | IC50 |
23.2 μM
Compound: 52; EGCG
|
Induction of nitric oxide production in human U266 cells
Induction of nitric oxide production in human U266 cells
|
[PMID: 31330448] |
| U-87MG ATCC | IC50 |
18 μM
Compound: EGCG
|
Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 28654265] |
| U-937 | IC50 |
1 μM
Compound: 4, EGCG
|
Inhibition of telomerase in human U937 cells
Inhibition of telomerase in human U937 cells
|
[PMID: 22413845] |
| Vero | IC50 |
16 μM
Compound: (-)-EGCG
|
Antiviral activity against Human herpesvirus 1 isolate P32 infected in African green monkey vero cells assessed as reduction in viral titer
Antiviral activity against Human herpesvirus 1 isolate P32 infected in African green monkey vero cells assessed as reduction in viral titer
|
[PMID: 18195068] |
| Vero | IC50 |
18.3 μM
Compound: (-)-EGCG
|
Antiviral activity against Human herpesvirus 1 isolate P56 infected in African green monkey vero cells assessed as reduction in viral titer
Antiviral activity against Human herpesvirus 1 isolate P56 infected in African green monkey vero cells assessed as reduction in viral titer
|
[PMID: 18195068] |
| Vero | IC50 |
45.36 μM
Compound: (-)-EGCG
|
Antiviral activity against Human herpesvirus 1 isolate P25 infected in African green monkey vero cells assessed as reduction in viral titer
Antiviral activity against Human herpesvirus 1 isolate P25 infected in African green monkey vero cells assessed as reduction in viral titer
|
[PMID: 18195068] |
| Vero | IC50 |
48.18 μM
Compound: (-)-EGCG
|
Antiviral activity against Human herpesvirus 1 isolate P38 infected in African green monkey vero cells assessed as reduction in viral titer
Antiviral activity against Human herpesvirus 1 isolate P38 infected in African green monkey vero cells assessed as reduction in viral titer
|
[PMID: 18195068] |
| Vero | IC50 |
48.41 μM
Compound: (-)-EGCG
|
Antiviral activity against Human herpesvirus 1 isolate P15 infected in African green monkey vero cells assessed as reduction in viral titer
Antiviral activity against Human herpesvirus 1 isolate P15 infected in African green monkey vero cells assessed as reduction in viral titer
|
[PMID: 18195068] |
| Vero | IC50 |
49.09 μM
Compound: (-)-EGCG
|
Antiviral activity against Human herpesvirus 1 isolate P42 infected in African green monkey vero cells assessed as reduction in viral titer
Antiviral activity against Human herpesvirus 1 isolate P42 infected in African green monkey vero cells assessed as reduction in viral titer
|
[PMID: 18195068] |
| Vero | IC50 |
72.3 μM
Compound: (-)-EGCG
|
Antiviral activity against Human herpesvirus 1 F1 infected in African green monkey vero cells assessed as reduction in viral titer
Antiviral activity against Human herpesvirus 1 F1 infected in African green monkey vero cells assessed as reduction in viral titer
|
[PMID: 18195068] |
In Vitro
(-)-Epigallocatechin Gallate (EGCG, 10-60 μM) inhibits the growth of FB-2 and WRO cells in a dose-dependent manner[1]. (-)-Epigallocatechin Gallate (10-60 μM, 0-24 h) reduces cyclin D1 and phosphorylation of AKT and ERK1/2, and increases p21 and p53 expression[1]. (-)-Epigallocatechin Gallate (10-60 μM, 12 h) reduces cell motility and migration[1]. (-)-Epigallocatechin Gallate (0-20 μM, 0-20 min approximately) inhibits GLUD1/2 and IDH1 activity in a concentration and time-dependent way (biochemical assays)[2]. (-)-Epigallocatechin Gallate (0-35 μg/mL, 24-72 h) inhibits the proliferation of colorectal cancer cells (LoVo, SW480, HT-29, HCT-8 cells), increases cell apoptosis and blocks cells at the G0/G1 phase[3]. (-)-Epigallocatechin Gallate (30 μM, 3-24 h) suppresses the expression of COX-2 and mPGES-1 mRNAs, prostaglandin E2 production in LPS-induced osteoblasts[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:FB-2 and WRO cells (serum-starved for 48h)
-
Concentration:10, 40, 60 μM.
-
Incubation Time:4 days
-
Result:Inhibited basal cell proliferation (40% in FB-2 and 35% in WRO) at 10 μM, inhibited cell number (by 68% to 73%) at 40 and 60 μM).
-
Cell Line:FB-2 cells
-
Concentration:10, 40, 60 μM.
-
Incubation Time:24 h
-
Result:Reduced cyclin D1 level, phosphorylation of AKT and ERK1/2. Induced the expression of p21 and p53, and E-cadherin, N-cadherin, Vimentin and α5-integrin.
-
Cell Line:FB-2 and WRO cells (serum-starved for 48h)
-
Concentration:10, 40, 60 μM.
-
Incubation Time:12 h
-
Result:Reduced migration activity in FB-2 and WRO cells.
-
Cell Line:Mouse primary osteoblasts (1 ng/ml LPS-treated)
-
Concentration:30 μM
-
Incubation Time:3, 6, 12, 24 h
-
Result:Suppressed the LPS-induced expression of COX-2 and mPGES-1 mRNAs, prostaglandin E2 production.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Orthotopic transplant BALB/c nude mice model[3]
-
Dosage:5, 10, and 20 mg/kg, once daily for 14 days.
-
Administration:Intragastrical administration.
-
Result:Inhibited tumors growth with no liver or lung metastases.
-
Animal Model:Model of experimental periodontitis, LPS (25 μg/mouse)[4]
-
Dosage:0.5 mg/mouse, a single dose.
-
Administration:Injected into the mouse lower gingiva
-
Result:Inhibited the LPS-induced loss of bone mineral density (BMD) in mice.
Chemical Information
-
CAS No. 989-51-5
-
Appearance Solid
-
Molecular Weight 458.37
-
Formula C22H18O11
-
Color Off-white to pink
-
SMILES
O=C(O[C@H]1[C@@H](C2=CC(O)=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3C1)C4=CC(O)=C(O)C(O)=C4
-
Synonyms
EGCG; Epigallocatechol Gallate
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (65)
-
Journal Impact Factor
-
Most Recent
-
Cancer Res
GOT2 Silencing Promotes Reprogramming of Glutamine Metabolism and Sensitizes Hepatocellular Carcinoma to Glutaminase Inhibitors. [Abstract]2022 Sep 16;82(18):3223-3235. PMID: 35895805 -
J Nanobiotechnology
Single-cell multi-omics analysis reveals the mechanism of action of a novel antioxidant polyphenol nanoparticle loaded with STAT3 agonist in mediating cardiomyocyte ferroptosis to ameliorate age-related heart failure. [Abstract]2025 Mar 29;23(1):258. PMID: 40158134
(-)-Epigallocatechin Gallate purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2025 Mar 29;23(1):258. [Abstract]
(A) Schematic diagram of the synthesis steps of PN@Col nanoparticles(61 mg (-)-Epigallocatechin Gallate (EGCG), 10 mg Glycine and 2 mg Colivelin);(B) Morphological features of PN (top) and PN@Col (bottom) observed using TEM (scale bar: 100 nm/200 nm);(C) Morphology of PN (top) and PN@Col (bottom) observed using SEM (scale bar: 5 μm/1 μm);
-
-
Biomaterials
Polyphenol-assisted facile assembly of bioactive nanoparticles for targeted therapy of heart diseases. [Abstract]2021 Aug:275:120952. PMID: 34147720 -
J Control Release
Dual-responsive antibacterial hydrogels encapsulating Periodontal Ligament Stem Cells for macrophage reprogramming and diabetic wound healing. [Abstract]2026 May 10:393:114824. PMID: 41833924 -
Cell Death Dis
RHBDL2 drives lipid metabolic reprogramming in osteosarcoma via USP3-mediated deubiquitination of PPT1. [Abstract]2026 Apr 24;17(1):548. PMID: 42031733 -
Cell Death Dis
Epigenetic activation of secretory phenotypes in senescence by the FOXQ1-SIRT4-GDH signaling. [Abstract]2023 Jul 29;14(7):481. PMID: 37516739
(-)-Epigallocatechin Gallate purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2023 Jul 29;14(7):481. [Abstract]
Growth curves of 2BS cells treated with DMSO (control), R162 (2 nM) or (-)-Epigallocatechin Gallate (EGCG, 10 nM; 2-6 days) were determined by CCK-8 assay.
-
Phytomedicine
Polyphenol extract ameliorates diabetes-related atherosclerosis through HIF-1 signaling pathway in APOE-/- mice: Possible synergism with atorvastatin. [Abstract]2025 May:140:156572. PMID: 40023112 -
Phytomedicine
Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]2025 May:140:156484. PMID: 40090046 -
Food Res Int
Effect of tea polyphenol binding to soybean β-conglycinin and glycinin on structure, aggregation, allergenicity and in vitro digestion characteristics. [Abstract]2025 Oct:218:116882. PMID: 40790684 -
EMBO Mol Med
In vitro and in vivo inhibition of the host TRPC4 channel attenuates Zika virus infection. [Abstract]2024 Aug;16(8):1817-1839. PMID: 39009885
(-)-Epigallocatechin Gallate purchased from MedChemExpress. Usage Cited in: EMBO Mol Med. 2024 Aug;16(8):1817-1839. [Abstract]
The ZIKV (2 × 106 PFU) samples were incubated with the indicated compounds (HC-070 (2.5 and 5 μM), KN-93 (5 and 10 μM), or (-)-Epigallocatechin Gallate (EGCG, 25 μM) or an equal volume of vehicle at 4 °C, 25 °C, and 37 °C for a duration of 1 h. Subsequently, the infectious viral particles in each sample were quantified using the PFU assay (n = 3 biological replicates). EGCG was employed as the positive control. Neither HC-070 nor KN-93 exhibited any impact on the infectivity of ZIKV particles in vitro.
-
ACS Appl Mater Interfaces
Engineering Assembly of Metal-Phenolic Nanoparticles with High Biocompatibility for Tumor Therapy. [Abstract]2025 Oct 15;17(41):56846-56860. PMID: 41043008 -
Br J Cancer
G3BP1 interacts with YWHAZ to regulate chemoresistance and predict adjuvant chemotherapy benefit in gastric cancer. [Abstract]2021 Jan;124(2):425-436. PMID: 32989225
(-)-Epigallocatechin Gallate purchased from MedChemExpress. Usage Cited in: Br J Cancer. 2021 Jan;124(2):425-436. [Abstract]
The IC50 values of capecitabine and oxaliplatin combined with or without (-)-Epigallocatechin Gallate (EGCG) treatment (25 μM, 48 h) were examined by CCK-8 assay. The results showed that pharmacological inhibition of G3BP1 with the specific inhibitor EGCG greatly reduced the IC50 of capecitabine and oxaliplatin.
-
Aging Cell
Testicular Lmcd1 regulates phagocytosis by Sertoli cells through modulation of NFAT1/Txlna signaling pathway. [Abstract]2020 Oct;19(10):e13217. PMID: 32840323
(-)-Epigallocatechin Gallate purchased from MedChemExpress. Usage Cited in: Aging Cell. 2020 Oct;19(10):e13217. [Abstract]
540-day-old mice received intraperitoneal (i.p.) injections of (-)-Epigallocatechin Gallate (EGCG; 50 mg/kg) for 3 consecutive days, followed by a 4-day break. This cycle was repeated for a total of 4 times. Following EGCG treatment, testes from different ages of mice were subjected to immunoblotting analysis.
-
Anal Chem
Noninvasive Dynamic Cell Viability Monitoring Based on Diffraction Height Fingerprint Spectra. [Abstract]2025 Dec 19. PMID: 41417584 -
J Med Chem
Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases. [Abstract]2023 Mar 23;66(6):4106-4130. PMID: 36876904 -
Anal Chem
Molecular Imaging and In Situ Quantitative Profiling of Fatty Acid Synthase with a Chemical Probe. [Abstract]2020 Mar 17;92(6):4419-4426. PMID: 32053360 -
J Agric Food Chem
Dual-Shell Chitosan/Ferritin Nanocages Enhance the Stability, Intestinal Transport, and Antiviral Activity of EGCG against HBV. [Abstract]2026 Apr 15;74(14):11579-11591. PMID: 41927466 -
-
Biochem Pharmacol
Targeting glutamine catabolism suppresses eosinophil expansion and activation to alleviate allergic airway inflammation. [Abstract]2025 Dec;242(Pt 4):117443. PMID: 41125213 -
Cell Mol Life Sci
An active glutamine/α-ketoglutarate/HIF-1α axis prevents pregnancy loss by triggering decidual IGF1+GDF15+NK cell differentiation. [Abstract]2022 Nov 30;79(12):611. PMID: 36449080 -
Food Funct
Improving the in vitro and in vivo bioavailability of pterostilbene using Yesso scallop gonad protein isolates-epigallocatechin gallate (EGCG) conjugate-based emulsions: effects of carrier oil. [Abstract]2022 Sep 22;13(18):9544-9558. PMID: 35997033 -
Cells
Identification of Natural Compounds Triggering MRGPRX2-Mediated Calcium Flux and Degranulation in RBL-2H3 Cells. [Abstract]2026 Feb 3;15(3):287. PMID: 41677650 -
Int Immunopharmacol
Environmental pollutants, bisphenol A and di(2-ethylhexyl) phthalate, induce spontaneous dermatitis-like skin lesions via TLR4/NF-κB/ferroptosis. [Abstract]2026 Sep 1:184:116932. PMID: 42190412 -
ACS Omega
2025 Dec 8;10(50):62145-62156. PMID: 41476561 -
Food Sci Nutr
Targeting to Intensify M2 Macrophage Polarization Ameliorate Podocyte Lipid Accumulation and Damage by Tea Polyphenols via Activating SIRT1 in the Aged Model Rats With DKD. [Abstract]2025 Aug 11;13(8):e70736. PMID: 40801050 -
Food Sci Nutr
EGCG Alleviates H2O2-Induced Inflammatory Injury and Apoptosis in Bovine Mammary Epithelial Cells Through Nrf2 Pathway Activation and p38MAPK Pathway Inhibition. [Abstract]2025 Feb 25;13(3):e4687. PMID: 40008238 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
Sci Rep
EGCG activates Keap1/P62/Nrf2 pathway, inhibits iron deposition and apoptosis in rats with cerebral hemorrhage. [Abstract]2024 Dec 28;14(1):31474. PMID: 39732956 -
Nanomaterials
Epigallocatechin Gallate-Gold Nanoparticles Exhibit Superior Antitumor Activity Compared to Conventional Gold Nanoparticles: Potential Synergistic Interactions. [Abstract]2019 Mar 8;9(3):396. PMID: 30857226 -
Environ Toxicol Pharmacol
2026 Mar:122:104954. PMID: 41644025 -
Neurochem Res
Effect of Epigallocatechin-3-gallate on Stress-Induced Depression in a Mouse Model: Role of Interleukin-1β and Brain-Derived Neurotrophic Factor. [Abstract]2022 Nov;47(11):3464-3475. PMID: 35939172 -
J Neurosci
2025 Aug 27;45(35):e0523252025. PMID: 40769725 -
FASEB J
Plasminogen Activator Inhibitor 1 Controls Abdominal Aortic Aneurism Formation via the Modulation of TGF-β/Smad2/3 Signaling in Mice. [Abstract]2025 May 15;39(9):e70562. PMID: 40323694 -
Biochim Biophys Acta Mol Cell Res
(-)-Epigallocatechin-3-gallate promotes the dermal papilla cell proliferation and migration through the induction of VEGFA. [Abstract]2025 Mar;1872(3):119902. PMID: 39814186 -
Antiviral Res
Nafamostat mesylate as a broad-spectrum candidate for the treatment of flavivirus infections by targeting envelope proteins. [Abstract]2022 Jun;202:105325. PMID: 35460703 -
Fish Shellfish Immunol
EGCG alleviated Mn exposure-caused carp kidney damage via trpm2-NLRP3-TNF-α-JNK pathway: Oxidative stress, inflammation, and tight junction dysfunction. [Abstract]2023 Mar:134:108582. PMID: 36754155 -
Microbiol Spectr
2022 Apr 27;10(2):e0227621. PMID: 35404086 -
Microb Pathog
2024 Nov:196:106960. PMID: 39313132 -
Pathogens
2026 Mar 20;15(3):334. PMID: 41901787 -
Viruses
Pre-Clinical Evaluation of the Antiviral Activity of Epigalocatechin-3-Gallate, a Component of Green Tea, against Influenza A(H1N1)pdm Viruses. [Abstract]2023 Dec 16;15(12):2447. PMID: 38140688 -
Viruses
Antiviral Effect of Epigallocatechin Gallate via Impairing Porcine Circovirus Type 2 Attachment to Host Cell Receptor. [Abstract]2020 Feb 4;12(2):176. PMID: 32033244 -
Bioorg Med Chem
Identification of daurioxoisoporphine D and moringamine I as blood-brain barrier-permeable natural inhibitors of amyloid-β aggregation and neuronal toxicity. [Abstract]2026 Jul:138:118664. PMID: 42008955 -
J Cancer
2019 Oct 21;10(26):6543-6556. PMID: 31777584 -
Open Biol
MYH7 R453C induced cardiac remodelling via activating TGF-β/Smad2/3, ERK1/2 and Nox4/ROS/NF-κB signalling pathways. [Abstract]2024 Jun;14(6):230427. PMID: 38862020 -
Oral Dis
Epigallocatechin-3-gallate inhibits proliferation and induces apoptosis in odontogenic keratocyst keratinocytes. [Abstract]2019 May;25(4):1175-1184. PMID: 30811745 -
PeerJ
Epigallocatechin gallate protects MC3T3-E1 cells from cadmium-induced apoptosis and dysfunction via modulating PI3K/AKT/mTOR and Nrf2/HO-1 pathways. [Abstract]2024 May 28:12:e17488. PMID: 38827303 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607 -
Toxicol In Vitro
Epigallocatechin gallate alleviates mono-2-ethylhexyl phthalate-induced male germ cell pyroptosis by inhibiting the ROS/mTOR/NLRP3 pathway. [Abstract]2023 Sep:91:105626. PMID: 37286014 -
Int J Cosmet Sci
2016 Oct;38(5):512-23. PMID: 27009797 -
Biochem Biophys Res Commun
Combinatorial screening of a panel of FDA-approved drugs identifies several candidates with anti-Ebola activities. [Abstract]2020 Feb 19;522(4):862-868. PMID: 31806372 -
Biochem Biophys Res Commun
Effects of intracellular iron overload on cell death and identification of potent cell death inhibitors. [Abstract]2018 Sep 3;503(1):297-303. PMID: 29890135 -
Oncol Lett
Epigallocatechin-3-gallate induces apoptosis in acute promyelocytic leukemia cells via a SHP-1-p38α MAPK-Bax cascade. [Abstract]2017 Nov;14(5):6314-6320. PMID: 29113283
(-)-Epigallocatechin Gallate purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2017 Nov;14(5):6314-6320. [Abstract]
Effects of (-)-Epigallocatechin Gallate (EGCG) on the levels of SHP-1 and p-p38α protein expression in NB4 cells. NB4 cells were treated with 10, 20 and 30 µM EGCG for 24 h. Western blot analysis was used to detect SHP-1, p38α and p-p38α protein expression. EGCG, epigallocatechin-3-gallate; SHP-1, Src homology region 2 domain-containing phosphatase-1; p38α, p38α mitogen activated protein kinase; p-, phosphorylated.
-
-
Nan Fang Yi Ke Da Xue Xue Bao
[Wenyang Huazhuo Tongluo Formula promotes angiogenesis in systemic sclerosis dermal microvascular endothelial cells by regulating the Sema3A/Nrp1 pathway]. [Abstract]2026 Jun 20;46(6):1323-1330. PMID: 42343841 -
-
-
-
-
-
Biomed Pharmacother
Epigallocatechin-3-gallate confers protection against myocardial ischemia/reperfusion injury by inhibiting ferroptosis, apoptosis, and autophagy via modulation of 14-3-3η. [Abstract]2024 May:174:116542. PMID: 38574620 -
Sci Total Environ
Epigallocatechin gallate (EGCG) nanoselenium application improves tea quality (Camellia sinensis L.) and soil quality index without losing microbial diversity: A pot experiment under field condition. [Abstract]2024 Mar 1:914:169923. PMID: 38199344 -
-
Oxid Med Cell Longev
Epigallocatechin Gallate Relieved PM2.5-Induced Lung Fibrosis by Inhibiting Oxidative Damage and Epithelial-Mesenchymal Transition through AKT/mTOR Pathway. [Abstract]2022 Jun 6:2022:7291774. PMID: 35707275 -
Oxid Med Cell Longev
Clinical Relevance and Tumor Growth Suppression of Mitochondrial ROS Regulators along NADH:Ubiquinone Oxidoreductase Subunit B3 in Thyroid Cancer. [Abstract]2022 Jan 17;2022:8038857. PMID: 35087620
Solvent & Solubility
In Vitro:
DMSO : 70 mg/mL (152.72 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.54 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.54 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (286 KB)
-
SDS (598 KB)
- English - EN (598 KB)
- Français - FR (598 KB)
- Deutsch - DE (598 KB)
- Norwegian - NO (598 KB)
- Español - ES (598 KB)
- Swedish - SV (598 KB)
- Italian - IT (598 KB)
- Korean - KR (598 KB)
- Portuguese - PT (598 KB)
-
Handling Instructions (2659 KB)
References
[1]. De Amicis F, et al. Epigallocatechin gallate inhibits growth and Epithelial-to-Mesenchymal Transition in human thyroid carcinoma cell lines. J Cell Physiol. 2013 Apr 1. [Content Brief]
[2]. Peeters TH, et al. Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate. Cancer Metab. 2019 May 20;7:4. [Content Brief]
[3]. Jin H, et al. Epigallocatechin gallate inhibits the proliferation of colorectal cancer cells by regulating Notch signaling. Onco Targets Ther. 2013;6:145-53. [Content Brief]
[4]. Tsukasa Tominari; Epigallocatechin gallate (EGCG) suppresses lipopolysaccharide-induced inflammatory bone resorption, and protects against alveolar bone loss in mice. FEBS Open Bio. 2015 Jun 12;5:522-7. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1816 mL | 10.9082 mL | 21.8164 mL | 54.5411 mL |
| 5 mM | 0.4363 mL | 2.1816 mL | 4.3633 mL | 10.9082 mL | |
| 10 mM | 0.2182 mL | 1.0908 mL | 2.1816 mL | 5.4541 mL | |
| 15 mM | 0.1454 mL | 0.7272 mL | 1.4544 mL | 3.6361 mL | |
| 20 mM | 0.1091 mL | 0.5454 mL | 1.0908 mL | 2.7271 mL | |
| 25 mM | 0.0873 mL | 0.4363 mL | 0.8727 mL | 2.1816 mL | |
| 30 mM | 0.0727 mL | 0.3636 mL | 0.7272 mL | 1.8180 mL | |
| 40 mM | 0.0545 mL | 0.2727 mL | 0.5454 mL | 1.3635 mL | |
| 50 mM | 0.0436 mL | 0.2182 mL | 0.4363 mL | 1.0908 mL | |
| 60 mM | 0.0364 mL | 0.1818 mL | 0.3636 mL | 0.9090 mL | |
| 80 mM | 0.0273 mL | 0.1364 mL | 0.2727 mL | 0.6818 mL | |
| 100 mM | 0.0218 mL | 0.1091 mL | 0.2182 mL | 0.5454 mL |